Lockshin et al developed a scoring system for measuring a flare in activity for patients with systemic lupus erythematosus (SLE). They used the score to evaluate women during pregnancy. Changes in the score can be monitored over time and can be used to assess effectiveness of interventions. The authors were from 4 hospitals in New York City.
Symptoms and signs:
(1) alopecia
(2) rash
(3) fever
(4) serositis
(5) arthralgia and/or arthritis
(6) mucosal ulcers
(7) neurologic events
(8) malaise
(9) fundi
(10) lymph nodes
(11) spleen
(12) miscellaneous (Coombs-positive hemolytic anemia, cutaneous vasculitis, etc.)
Laboratory data:
(13) erythrocyte sedimentation rate (ESR)
(14) anti-DNA antibody
(15) complement
(16) serum creatinine
(17) urine red blood cells per high power field
(18) urine protein
(19) hemoglobin
(20) platelet count
Parameter |
Finding |
Points |
---|---|---|
alopecia |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
rash |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
fever |
<= 38°C |
0 |
|
38.1 – 39°C |
1 |
|
> 39.0°C |
2 |
serositis |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
arthralgias and/or arthritis |
none |
0 |
|
arthralgias |
1 |
|
arthritis |
2 |
mucosal ulcers |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
neurologic events |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
malaise |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
fundi |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
lymph nodes |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
spleen |
nonpalpable |
0 |
|
palpable |
2 |
miscellaneous finding |
none |
0 |
|
moderate |
1 |
|
marked |
2 |
ESR |
<= 25 mm/h |
0 |
|
26 – 75 mm/h |
1 |
|
> 75 mm/h |
2 |
anti-DNA antibody |
none or low titer |
0 |
|
moderate titer |
1 |
|
high titer |
2 |
complement |
normal (>= 150 U/mL) |
0 |
|
moderate decrease (101 – 150 U/mL) |
1 |
|
marked decrease (<= 100 U/mL) |
2 |
creatinine |
< 0.2 mg/dL |
0 |
|
0.2 – 1.0 mg/dL |
1 |
|
> 1.0 mg/dL |
2 |
urine RBCs |
0 – 3 per hpf (high power field) |
0 |
|
4 – 10 per hpf |
1 |
|
> 10 per hpf |
2 |
urine protein |
0, or <= 0.3 g per 24 h |
0 |
|
trace to 2+, or 0.31 – 2.0 g per 24 h |
1 |
|
3+ to 4+, or > 2.0 g per 24 h |
2 |
hemoglobin |
>= 13 g/dL |
0 |
|
10.0 – 12.9 g/dL |
1 |
|
< 10.0 g/dL |
2 |
platelet count |
>= 150,000 per µL |
0 |
|
50,000 – 149,999 per µL |
1 |
|
< 50,000 per µL |
2 |
score =
= SUM(points for all 20 parameters)
Interpretation:
• minimum score: 0
• maximum score: 40
• The higher the score, the greater the flare in activity.
• The lower the score, the lower the activity and remission.
Purpose: To use the score of Lockshin et al for evaluating disease activity in a patient with SLE.
Specialty: Immunology/Rheumatology
Objective: severity, prognosis, stage
ICD-10: M32,